Chronic obstructive pulmonary disease (COPD) is an inflammatory condition with constantly
increasing mortality rates. Interleukin (IL)-33 and its decoy receptor, soluble suppression of …

Soluble ST2 (sST2) is upregulated in response to myocardial stress and may serve as
biomarker in adults with pulmonary hypertension (PH). This prospective cohort study …

Background: Serum concentrations of ST2 (interleukin-1 receptor-like 1) represent a
meaningful prognostic marker in cardiac diseases. Production of soluble ST2 (sST2) may be …

Background Idiopathic pulmonary fibrosis (IPF) is a heterogeneous and progressive
fibrosing interstitial lung disease with a poor prognosis. However, there are currently no …

BACKGROUND ST2, part of the interleukin-1 receptor family, is released from cardiac
myocytes under mechanical strain. Soluble ST2 (sST2) concentrations are associated with …

Background Soluble suppression of tumorigenicity (sST2) has been proposed to be a
marker for biomechanical strain and a possible predictor of mortality in patients with chronic …

Background Soluble ST2 is a biomarker that is elevated in certain systemic inflammatory
diseases. Comorbidity‐driven microvascular inflammation is postulated to play a key role in …

In recent years, numerous studies have focused on the use of soluble ST2 (sST2) as a
clinical biomarker for cardiovascular disease. However, much preclinical data points to …

Purpose sST2 (soluble suppression of tumorigenicity 2), a member of the interleukin-1
family, has been suggested to play a role in cardiac remodeling and inflammatory signaling …

Background Neutrophilic inflammation is associated with poorly controlled asthma. Serum
levels of sST2, a soluble IL-33 receptor, increase in neutrophilic lung diseases. We …